These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8252498)

  • 21. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nilutamide-induced acute hepatitis].
    Hammel P; Ducreux M; Bismuth E; Ladouch-Badre A; Benoit G; Buffet C; Etienne JP
    Gastroenterol Clin Biol; 1991; 15(6-7):557. PubMed ID: 1916139
    [No Abstract]   [Full Text] [Related]  

  • 24. [Fatal fulminating hepatitis induced by nilutamide].
    Edouard A; Robinel R; Rat C; Lombard F; Lorinet C; Escarmant P
    Gastroenterol Clin Biol; 2003 Dec; 27(12):1170-1. PubMed ID: 14770126
    [No Abstract]   [Full Text] [Related]  

  • 25. Androgen blockade in prostate cancer.
    Labrie F; Candas B
    Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
    [No Abstract]   [Full Text] [Related]  

  • 26. Lung caught in Nilutamide treatment.
    Lourenço EP; Nzwalo H; Sampaio MR; Brito H
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27599808
    [No Abstract]   [Full Text] [Related]  

  • 27. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996].
    Lansiaux P
    Prog Urol; 1997 Dec; 7(6):1020-2. PubMed ID: 9490132
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

  • 30. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The kinetics of antiandrogens in humans.
    Tremblay D; Dupront A; Meyer BH; Pottier J
    Prog Clin Biol Res; 1987; 243A():341-50. PubMed ID: 2958859
    [No Abstract]   [Full Text] [Related]  

  • 32. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H
    Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
    [No Abstract]   [Full Text] [Related]  

  • 34. Androgen blockade and suppression for prostate carcinoma.
    Lancet; 1989 Oct; 2(8670):1020. PubMed ID: 2572747
    [No Abstract]   [Full Text] [Related]  

  • 35. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
    Soloway MS; Matzkin H
    Cancer; 1993 Feb; 71(3 Suppl):1083-8. PubMed ID: 8428332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.
    Akoun GM; Liote HA; Liote F; Gauthier-Rahman S; Kuntz D
    Chest; 1990 Feb; 97(2):495-8. PubMed ID: 2298082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute depressive syndrome possibly due to nilutamide (Anandron) treatment].
    Maroy B; Pitrou P
    Therapie; 1997; 52(1):79-81. PubMed ID: 9183930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.